Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for ...
Fortress Biotech, Inc. and its subsidiary Helocyte, Inc. have initiated a Phase 2 clinical trial to assess the efficacy of the Triplex vaccine, designed to prevent cytomegalovirus (CMV) reactivation ...
The IE86 protein of human cytomegalovirus is an 'immediate early' viral protein that drives cells into S phase, but blocks cell division. In the March 5 Proceedings of the National Academy of Sciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback